Cancer Cachexia: Mechanisms and Clinical Implications

被引:172
作者
Donohoe, Claire L. [1 ]
Ryan, Aoife M. [2 ]
Reynolds, John V. [1 ]
机构
[1] St James Hosp, Trinity Coll Dublin, Trinity Ctr Hlth Sci, Dept Surg, Dublin 8, Ireland
[2] NYU, Dept Nutr Food Studies & Publ Hlth, New York, NY 10003 USA
关键词
QUALITY-OF-LIFE; PROTEOLYSIS-INDUCING FACTOR; LIPID-MOBILIZING FACTOR; NECROSIS-FACTOR-ALPHA; ACUTE-PHASE RESPONSE; CELL LUNG-CANCER; 5 DIFFERENT ARMS; WEIGHT-LOSS; SYSTEMIC INFLAMMATION; DOUBLE-BLIND;
D O I
10.1155/2011/601434
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Cachexia is a multifactorial process of skeletal muscle and adipose tissue atrophy resulting in progressive weight loss. It is associated with poor quality of life, poor physical function, and poor prognosis in cancer patients. It involves multiple pathways: procachectic and proinflammatory signals from tumour cells, systemic inflammation in the host, and widespread metabolic changes (increased resting energy expenditure and alterations in metabolism of protein, fat, and carbohydrate). Whether it is primarily driven by the tumour or as a result of the host response to the tumour has yet to be fully elucidated. Cachexia is compounded by anorexia and the relationship between these two entities has not been clarified fully. Inconsistencies in the definition of cachexia have limited the epidemiological characterisation of the condition and there has been slow progress in identifying therapeutic agents and trialling them in the clinical setting. Understanding the complex interplay of tumour and host factors will uncover new therapeutic targets.
引用
收藏
页数:13
相关论文
共 138 条
  • [1] AGTERESCH HJ, 2004, NUTR CLIN PRACT, V19, P413
  • [2] Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?
    Andreyev, HJN
    Norman, AR
    Oates, J
    Cunningham, D
    [J]. EUROPEAN JOURNAL OF CANCER, 1998, 34 (04) : 503 - 509
  • [3] [Anonymous], COCHRANE DATABASE SY
  • [4] ESPEN guidelines on enteral nutrition:: Non-surgical oncology
    Arends, J.
    Bodoky, G.
    Bozzetti, F.
    Fearon, K.
    Muscaritoli, M.
    Selga, G.
    van Bokhorst-de van der Schuereng, M. A. E.
    von Meyenfeldt, M.
    Zuercher, G.
    Fietkau, R.
    Aulbert, E.
    Frick, B.
    Holm, M.
    Kneba, M.
    Mestrom, H. J.
    Zander, A.
    [J]. CLINICAL NUTRITION, 2006, 25 (02) : 245 - 259
  • [5] Cancer cachexia:: the molecular mechanisms
    Argilés, JM
    Moore-Carrasco, R
    Fuster, G
    Busquets, S
    López-Soriano, FJ
    [J]. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2003, 35 (04) : 405 - 409
  • [6] Argilés JM, 2001, MED RES REV, V21, P83, DOI 10.1002/1098-1128(200101)21:1<83::AID-MED4>3.0.CO
  • [7] 2-1
  • [8] Cachexia worsens prognosis in patients with resectable pancreatic cancer
    Bachmann, Jeannine
    Heiligensetzer, Mathias
    Krakowski-Roosen, Holger
    Buechler, Markus W.
    Friess, Helmut
    Martignoni, Marc E.
    [J]. JOURNAL OF GASTROINTESTINAL SURGERY, 2008, 12 (07) : 1193 - 1201
  • [9] The effect of an oral nutritional supplement enriched with fish oil on weight loss in patients with pancreatic cancer
    Barber, MD
    Ross, JA
    Voss, AC
    Tisdale, MJ
    Fearon, KCH
    [J]. BRITISH JOURNAL OF CANCER, 1999, 81 (01) : 80 - 86
  • [10] A randomized, double-blind, placebo-controlled trial of a β-hydroxyl β-methyl butyrate, glutamine, and arginine mixture for the treatment of cancer cachexia (RTOG 0122)
    Berk, Lawrence
    James, Jennifer
    Schwartz, Anna
    Hug, Eugen
    Mahadevan, Anand
    Samuels, Michael
    Kachnic, Lisa
    [J]. SUPPORTIVE CARE IN CANCER, 2008, 16 (10) : 1179 - 1188